SCHEMBL13348751

SCHEMBL13348751

CC(=S)Nc1ncc2cccc(O)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.41
METAP2 P50579 2/20 0.41
PLAU P00749 1/20 0.41
NCF1 P14598 1/20 0.41
TSHR P16473 2/20 0.40
MMP2 P08253 1/20 0.40
CHRM1 P11229 1/20 0.40
COMT P21964 1/20 0.40
ADRA1A P35348 1/20 0.40
METAP1 P53582 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
ALOX12 P18054 3/20 0.38
CDK1 P06493 1/20 0.38
CDK4 P11802 1/20 0.38
CCNB1 P14635 1/20 0.38
CCND1 P24385 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
PIM1 P11309 1/20 0.37
MAPK10 P53779 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13313228 0.86 CYP1A2 (0.46) KDM4EMETAP2PLAUNCF1TSHR
SCHEMBL13348748 0.84 DYRK1A (0.49) KDM4EMETAP2PLAUNCF1TSHR
SCHEMBL13348749 0.81 JAK2 (0.53) KDM4ECDK1CDK4CCNB1CCND1
SCHEMBL3246319 0.80 KDM4E (0.46) KDM4EMETAP2PLAUNCF1TSHR
SCHEMBL3243440 0.79 PIM1 (0.49) KDM4EMETAP2PLAUNCF1TSHR
SCHEMBL13313211 0.76 KDM4E (0.45) KDM4EMETAP2PLAUNCF1TSHR
SCHEMBL27640664 0.72 PLAU (0.44) KDM4EMETAP2PLAUNCF1TSHR
SCHEMBL3234136 0.71 METAP2 (0.55) KDM4EMETAP2PLAUNCF1TSHR
SCHEMBL1041168 0.71 PLAU (0.55) KDM4EMETAP2PLAUNCF1TSHR
SCHEMBL3268407 0.71 KCNH3 (0.43) HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-24 US disclosed
US-7692011-B2 8-hydroxy and 8-mercapto quinazolinones PRANA BIOTECHNOLOGY LIMITED (AU) 2010-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS ACHE, PSEN1, PSEN2 KDM4E 3329/4885METAP2 1931/4885PLAU 2406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.